Mark A. Goldsmith - 25 Nov 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
25 Nov 2025
Net transactions value
-$4,709,562
Form type
4
Filing time
26 Nov 2025, 16:15:45 UTC
Previous filing
20 Nov 2025
Next filing
18 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOLDSMITH MARK A President and Chief Executive Officer, Director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 26 Nov 2025 0001246842

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $245,400 +60,000 +24% $4.09 307,863 25 Nov 2025 Direct F1, F2
transaction RVMD Common Stock Sale $4,504,962 -60,000 -19% $75.08 247,863 25 Nov 2025 Direct F1, F2, F3
transaction RVMD Common Stock Sale $225,000 -3,000 -4.3% $75.00 67,424 25 Nov 2025 Trust F4
transaction RVMD Common Stock Sale $225,000 -3,000 -4.3% $75.00 67,424 25 Nov 2025 Trust F5
holding RVMD Common Stock 570,050 25 Nov 2025 Trust F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -60,000 -44% $0.000000 77,708 25 Nov 2025 Common Stock 60,000 $4.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.
F2 Includes 193,475 restricted stock units.
F3 This transaction was executed in multiple trades at prices ranging from $75.00 to $75.3650. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 Held by Jonathan Goldsmith Revocable Trust.
F5 Held by Rebecca Goldsmith Revocable Trust.
F6 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer